Product Information

NAPROXEN 125 MG/5 ML SUSPEN is a generic product labeled by Camber Pharmaceuticals Inc., priced at $0.2018 per ML under NDC 31722068205. Its NADAC has been published 133 times since Mar 20, 2024.

FDA first approved this application on Jun 7, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

NAPROXEN 125 MG/5 ML SUSPEN

Naproxen
$0.2018per ML

Strength

25 mg/mL

NDC

31722068205

Classification

Generic

Dosage Form

SUSPENSION

Route

ORAL

Effective Date

9/23/2026

Active Ingredients

NAPROXEN

Approval Type

Generic (ANDA)

FDA Application

ANDA215776

FDA Approved

6/7/2022

TE Code

AB

On Market Since

6/7/2022

Pharmacological Classes

Anti-Inflammatory Agents
Non-Steroidal
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug

Price Statistics

The NADAC for NAPROXEN 125 MG/5 ML SUSPEN has been published 133 times since Mar 20, 2024, and over the history we have for it it has declined 78.0%. The table below summarizes its recorded NADAC range and movement.

Current price$0.2018 per ML
All-time high$0.9187 (Apr 10, 2024)
All-time low$0.1654 (Mar 18, 2026)
52-week high$0.2346
52-week low$0.1654
Median price$0.2841
Average price$0.3533
Largest weekly change-33.2% (Oct 23, 2024)
Weeks tracked133
Tracking sinceMar 20, 2024

Price History

1W

0.0%

1M

+5.5%

3M

+14.6%

6M

+22.0%

1Y

-12.6%

3Y

N/A

5Y

N/A

All

-78.0%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 40% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 40%

1 alternative • Same active ingredient

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of NAPROXEN 125 MG/5 ML SUSPEN?

The current National Average Drug Acquisition Cost (NADAC) for NAPROXEN 125 MG/5 ML SUSPEN, manufactured by Camber Pharmaceuticals Inc., is $0.2018 per ML (NDC 31722068205), effective Sep 30, 2026.

How has the price of NAPROXEN 125 MG/5 ML SUSPEN changed over time?

Over the history we have for it, the NADAC for NAPROXEN 125 MG/5 ML SUSPEN has declined 78.0%. It has been tracked across 133 weekly CMS publications since Mar 20, 2024.

What are the highest and lowest recorded NADAC prices for NAPROXEN 125 MG/5 ML SUSPEN?

Since Mar 20, 2024, the NADAC for NAPROXEN 125 MG/5 ML SUSPEN has ranged from a low of $0.1654 (Mar 18, 2026) to a high of $0.9187 (Apr 10, 2024), with a median of $0.2841 per ML.

Are there cheaper alternatives to NAPROXEN 125 MG/5 ML SUSPEN?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, NAPROXEN 125 MG/5 ML SUSPEN, is $0.1216 per ML — about 40% below NAPROXEN 125 MG/5 ML SUSPEN.

Who manufactures NAPROXEN 125 MG/5 ML SUSPEN?

NAPROXEN 125 MG/5 ML SUSPEN (NDC 31722068205) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.